1. Home
  2. ALTO vs ADCT Comparison

ALTO vs ADCT Comparison

Compare ALTO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ALTO

Alto Ingredients Inc.

HOLD

Current Price

$5.15

Market Cap

420.7M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.14

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTO
ADCT
Founded
2003
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.7M
431.2M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
ALTO
ADCT
Price
$5.15
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
2.6M
3.1M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
119.51
30.86
EPS
0.05
N/A
Revenue
$917,927,000.00
$81,357,000.00
Revenue This Year
$6.66
N/A
Revenue Next Year
$0.43
$66.49
P/E Ratio
$104.40
N/A
Revenue Growth
N/A
14.85
52 Week Low
$0.92
$0.78
52 Week High
$6.00
$4.98

Technical Indicators

Market Signals
Indicator
ALTO
ADCT
Relative Strength Index (RSI) 48.13 22.25
Support Level $4.27 $0.78
Resistance Level $5.98 $4.77
Average True Range (ATR) 0.36 0.16
MACD -0.06 0.00
Stochastic Oscillator 27.39 15.43

Price Performance

Historical Comparison
ALTO
ADCT

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: